Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non–Small-Cell Lung Cancer Previously Treated With Immunotherapy—Lung-MAP S1800A

por Reckamp, Karen L., Redman, Mary W., Dragnev, Konstantin H., Minichiello, Katherine, Villaruz, Liza C., Faller, Bryan, Al Baghdadi, Tareq, Hines, Susan, Everhart, Leah, Highleyman, Louise, Papadimitrakopoulou, Vassiliki, Gandara, David R., Kelly, Karen, Herbst, Roy S.
Publicado 2022

Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical Trial

por Gettinger, Scott N., Redman, Mary W., Bazhenova, Lyudmila, Hirsch, Fred R., Mack, Philip C., Schwartz, Lawrence H., Bradley, Jeffrey D., Stinchcombe, Thomas E., Leighl, Natasha B., Ramalingam, Suresh S., Tavernier, Susan S., Yu, Hui, Unger, Joseph M., Minichiello, Katherine, Highleyman, Louise, Papadimitrakopoulou, Vassiliki A., Kelly, Karen, Gandara, David R., Herbst, Roy S.
Publicado 2021

Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400...

por Leighl, Natasha B, Redman, Mary W, Rizvi, Naiyer, Hirsch, Fred R, Mack, Philip C, Schwartz, Lawrence H, Wade, James L, Irvin, William J, Reddy, Sreekanth C, Crawford, Jeffrey, Bradley, Jeffrey D, Stinchcombe, Thomas E, Ramalingam, Suresh S, Miao, Jieling, Minichiello, Katherine, Herbst, Roy S, Papadimitrakopoulou, Vassiliki A, Kelly, Karen, Gandara, David R
Publicado 2021